ArticleACS omega2026
SNAP-Tag-Based Antibody-Drug Conjugates Targeting Epidermal Growth Factor Receptor 1, Epidermal Growth Factor Receptor 2, Trophoblast Cell-Surface Antigen 2, and Tissue Factor for Ovarian Cancer Treatment.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ovarian cancer is a heterogeneous and most malignant form of gynecologic cancer. Despite surgical intervention and systemic chemotherapy, treatment options for this cancer remain limited. Antibody-drug conjugate (ADC) represents a novel targeted therapy that uses an antibody to specifically deliver toxins to tumor sites. With the approval of the first ADC targeting ovarian cancer, more ADCs are currently under preclinical investigation or clinical trials to expand therapeutic options. In this study, we developed four ADCs targeting epidermal growth factor receptor (EGFR), epidermal growth factor receptor 2 (Her2), trophoblast cell-surface antigen 2 (Trop2), and tissue factor (TF) that are highly expressed on ovarian cancer cells. Our ADCs are constructed using single chain antibody fragments (scFvs) as the antibody backbone, with the cytotoxic agent monomethyl auristatin E conjugated via SNAP-tag technology, offering a high site-specific conjugation efficiency. All four ADCs preliminarily demonstrated specific binding and internalization, as verified by flow cytometry and fluorescence microscopy. Additionally, the ADCs exhibited potent and specific cytotoxicity in a dose-dependent manner in four ovarian cancer cell lines, inducing apoptosis at nanomolar concentrations. These constructs showed encouraging preliminary characteristics, although further studies are required to validate their therapeutic potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.